Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 9/20 | 0.45 |
| ▸ | RXRB | P28702 | 9/20 | 0.45 |
| ▸ | RXRG | P48443 | 6/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19197805 | 0.83 | CARM1 (0.45) | RXRARXRBRXRGBCL2L1BAD | |
| SCHEMBL31312989 | 0.80 | BCL2L1 (0.54) | RXRARXRBRXRGBCL2L1BAD | |
| SCHEMBL31180242 | 0.79 | STS (0.44) | RXRARXRBRXRGBCL2L1BAD | |
| SCHEMBL2262294 | 0.79 | BCL2L1 (0.42) | RXRARXRBRXRGBCL2L1BAD | |
| SCHEMBL31180258 | 0.77 | STS (0.42) | RXRARXRBRXRGBCL2L1BAD | |
| SCHEMBL10963407 | 0.76 | HSPB1 (0.47) | SMN1; SMN2NPSR1LMNA | |
| SCHEMBL13835216 | 0.75 | PDE4A (0.51) | RXRARXRBRXRGMRGPRX4MAOB | |
| SCHEMBL507354 | 0.73 | ST14 (0.52) | ST14HTTSMN1; SMN2DPP4L3MBTL1 | |
| SCHEMBL9719997 | 0.72 | RXRA (0.55) | RXRARXRBRXRGBCL2L1BAD | |
| SCHEMBL922347 | 0.71 | ST14 (0.60) | ST14RXRARXRBRXRGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | ST14 4642/4885RXRA 2534/4885RXRB 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.